Sequoia Financial Advisors LLC Increases Holdings in Cencora, Inc. $COR

Sequoia Financial Advisors LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 25.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,428 shares of the company’s stock after purchasing an additional 2,530 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Cencora were worth $4,197,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in COR. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Cencora by 13.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after acquiring an additional 5,543 shares during the period. AustralianSuper Pty Ltd purchased a new position in Cencora during the third quarter valued at approximately $26,191,000. Mediolanum International Funds Ltd grew its stake in Cencora by 133.0% during the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after acquiring an additional 32,138 shares in the last quarter. Chilton Investment Co. Inc. bought a new stake in Cencora during the 3rd quarter worth approximately $459,000. Finally, Advisors Asset Management Inc. lifted its stake in Cencora by 40.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock worth $5,407,000 after purchasing an additional 4,973 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Barclays boosted their price target on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Evercore set a $360.00 price objective on Cencora in a research report on Wednesday, April 8th. Wells Fargo & Company lifted their price objective on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Morgan Stanley set a $342.00 target price on Cencora in a research report on Friday. Finally, William Blair began coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $388.42.

Cencora Price Performance

Shares of NYSE:COR opened at $261.16 on Friday. The company’s fifty day moving average price is $327.81 and its 200-day moving average price is $342.26. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.51. The firm has a market capitalization of $50.80 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 1.21 and a beta of 0.64. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the prior year, the firm posted $4.42 earnings per share. The business’s revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities research analysts anticipate that Cencora, Inc. will post 17.73 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s payout ratio is 18.40%.

Key Headlines Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora raised FY2026 EPS guidance to $17.65-$17.90 and resumed a $1 billion share repurchase program, signaling management confidence in earnings power and capital returns.
• Positive Sentiment: Several Wall Street firms still maintained bullish ratings after cutting price targets, including Citi and Baird, suggesting analysts continue to see upside despite the selloff.
• Neutral Sentiment: Commentary around the stock emphasizes a “valuation debate” and whether the post-earnings decline was overdone, indicating investors are reassessing expectations rather than reacting to a new operational shock. Cencora NYSE Composite Reset Sparks Valuation Debate
• Neutral Sentiment: Analyst and media coverage is also centered on margin expansion versus growth, reflecting debate over whether Cencora is prioritizing profitability and buybacks over top-line momentum. Is Cencora (COR) Prioritizing Margin Expansion Over Growth With Its Raised EPS Outlook and Buybacks?
• Negative Sentiment: The main bearish driver is the earnings report, which missed EPS estimates and came with sales below analyst expectations, raising concerns about near-term growth momentum. Cencora (NYSE:COR) reports sales below analyst estimates in Q1 CY2026 earnings
• Negative Sentiment: A securities fraud investigation announcement could add overhang and legal-risk concerns, potentially worsening sentiment until more details are known. Securities Fraud Investigation Into Cencora, Inc. (COR) Announced

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.